Atogepant just met a late-stage study goal. Researchers say the results could help prevent an all-too-common condition that impacts millions of women.
Inc.com
This Migraine Condition Affects 1 in 3 Women. A Treatment Just Met a Phase 3 Goal
Shown as published in the source's RSS feed. IndiaAIFounders doesn't link out to third-party sites — this is the complete detail available from the feed itself.